Should all patients with immune‐mediated thrombotic thrombocytopenic purpura receive caplacizumab?
Adrien Picod, Agnès Veyradier, Paul Coppo
Topics & Concepts
MedicineVon Willebrand factorPlateletInternal medicineImmune systemImmunologyIntensive care medicineComplement system in diseasesPlatelet Disorders and TreatmentsRenal Diseases and Glomerulopathies